These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.

This document has been updated: Version 6 June 2022.

For translations of this document in other languages, click here.


Related links:


Archived versions:

Interim guidance for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine. Version 17 March 2021.

  • Position paper
  • Janssen COVID-19 Vaccine
  • COVID-19